Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XNW5004 in Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT06702605Phase 2Not yet recruiting
- Sponsor
- Evopoint Biosciences
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of igermetostat in peripheral T-cell lymphoma (PTCL), sponsored by Evopoint Biosciences. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
igermetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06702605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06702605.